Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
Q3 2024 Earnings Call November 7, 2024 5:00 AM ETCompany ParticipantsRune Sandager - Investor RelationsPeter Karlstromer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback